Objective: The small number of boys present in most studies on final height (FH) after gonadotropin-releasing hormone agonist (GnRHa) treatment for central precocious puberty (CPP) offers difficulties in the evaluation of the effects of treatment on FH in males. Method: We therefore combined FH data from The Netherlands, Italy and France to study the effect of GnRHa treatment in a large group of 26 boys with CPP. Results: The mean chronological age at the start of treatment was 7.6 ± 2.0 (SD) years, bone age (BA) was 11.0 ± 2.1 years. All boys were treated with depot formulations of the GnRHa triptorelin with established gonadal suppression for a mean treatment period of 4.7 ± 2.1 years. FH was 172.9 ± 6.6 cm. FH standard deviation score (SDS) was –0.66 ± 1.22, not significantly different from the target height SDS of –0.23 ± 0.75. FH-SDS was significantly lower in the subgroup of 12 patients with organic CPP compared to patients with idiopathic CPP (–1.34 ± 1.06 vs. –0.08 ± 1.06, respectively; p = 0.01), but no difference in height gain was observed. The mean estimated height gain, defined as the difference between predicted and actual adult height was 6.2 ± 8.7 cm using the average tables of Bayley and Pinneau, and 0.3 ± 8.6 cm using the BA advance adjusted tables. Regional differences in height gain were observed between the different countries, reflecting different local practices. Conclusion: We conclude that GnRHa treatment in boys results in a FH close to target height.

1.
Oostdijk W, Rikken B, Schreuder S, et al: Final height in central precocious puberty after long-term treatment with a slow-release GnRH agonist. Arch Dis Child 1996;75:292–297.
2.
Carel JC, Roger M, Ispas S, et al: Final height after long-term treatment with Triptorelin slow release for central precocious puberty: Importance of statural growth after interruption of treatment. J Clin Endocrinol Metab 1999;84:1973–1978.
3.
Mul D, Oostdijk W, Otten BJ, et al: Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: The Dutch experience. J Pediatr Endocrinol Metab 2000;13(suppl 1):765–772.
4.
Paul D, Conte FA, Grumbach MM, Kaplan SL: Long term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metab 1995;80:546–551.
5.
Bertelloni S, Baroncelli GI, Ferdeghini M, Menchini-Fabris F, Saggese G: Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur J Pediatr 2000;159:369–374.
6.
Galluzzi F, Salti R, Pasquini E, La Cauza C: Adult height comparison between boys and girls with precocious puberty after long-term gonadotrophin-releasing hormone analogue therapy. Acta Paediatr 1998;87:521–527.
7.
Brunner HG, Otten BJ: Precocious puberty in boys. N Engl J Med 1999;341:1763–1765.
8.
Abbassi V: Growth and normal puberty. Pediatrics 1998;102:507–511.
9.
Drop SLS, De Waal W, De Muinck Keizer-Schrama SMPF: Sex steroid treatment of constitutionally tall stature. Endocr Rev 1998;19:540–558.
10.
Zachmann M, Sobradillo B, Frank M, Frisch H, Prader A: Bayley-Pinneau, Roche-Wainer-Thissen, and Tanner height predictions in normal children and in patients with various pathologic conditions. J Pediatr 1978;93:749–755.
11.
Roede MJ, Wieringen JC van: Growth diagrams 1980. Netherlands third nation-wide survey. Tijdschr Soc Gezondheidszorg 1985;63(suppl):11–32.
12.
Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, and stages of puberty. Arch Dis Child 1976;51:170–179.
13.
Sempé M, Pédron G, Roy P: Auxologie, méthodes et séquences. Paris, Theraplix, 1979.
14.
Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of the Hand and Wrist, ed 2. Stanford, Stanford University Press, 1959.
15.
Bayley N, Pinneau SR: Tables for predicting adult height for skeletal age: Revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423–441.
16.
Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzelan A, Laron Z: Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method. Horm Res 1997;47:54–61.
17.
Thamdrup E: Precocious Sexual Development. Copenhagen, Munksgaard, 1961.
18.
Sigurjonsdottir TJ, Hayles AB: Precocious puberty. A report of 96 cases. Am J Dis Child 1968;115:309–321.
19.
Oerter KE, Manasco PK, Barnes KM, Jones J, Hill S, Cutler GB Jr: Effects of luteinizing hormone-releasing hormone agonists on final height in luteinizing hormone-releasing hormone-dependent precocious puberty. Acta Paediatr Suppl 1993;388:62–69.
20.
Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB Jr: Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999;84:175–178.
21.
Clementi M, Milani S, Mammi I, Boni S, Monciotti C, Tenconi R: Neurofibromatosis type 1 growth charts. Am J Med Genet 1999;87:317–323.
22.
Carmi D, Shohat M, Metzker A, Dickerman Z: Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: A longitudinal study. Pediatrics 1999;103:1257–1262.
23.
Virdis R, Sigorini M, Laiolo A, et al: Neurofibromatosis type I and precocious puberty. J Pediatr Endocrinol Metab 2000;13(suppl 1):841–844.
24.
Arrigo T, Cisternino M, Galluzzi F, et al: Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 1999;141:140–144.
25.
Palmert MR, Malin HV, Boepple PA: Unsustained or slowly progressive puberty in young girls: Initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999;84:415–423.
26.
Liu YX, Wikland KA, Karlberg J: New reference for the age at childhood onset of growth and secular trend in the timing of puberty in Swedish. Acta Paediatr 2000;89:637–643.
27.
Rizzo V, De Sanctis V, Corrias A, et al: Factors influencing final/near-final height in 12 boys with central precocious puberty treated with gonadotrophin-releasing hormone agonists. J Pediatr Endocrinol Metab 2000;13(suppl 1):781–786.
28.
Feuillan P, Merke D, Leschek EW, Cutler GB Jr: Use of aromatase inhibitors in precocious puberty. Endocr Relat Cancer 1999;6:303–306.
29.
Smith EP, Boyd J, Frank GR, et al: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056–1061.
30.
Bilezikian JP, Morishima A, Bell J, Grumbach MM: Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998;339:599–603.
31.
Lazar L, Pertzelan A, Weintrob N, et al: Sexual precocity in boys: Accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab 2001;86:4127–4132.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.